tickrz reports
Vertex Pharmaceuticals Inc (VRTX)
Healthcare | Drugs
155.30  -1.65%
VRTX vs DRUGS SECTOR & S&P 500
VALUATION
VRTXSECTORS&P 500
P/E RATIO201.9240.521.12
EV/EBITDA RATIO2092.98133.412.66
P/S RATIO17.226.52.25
P/B RATIO22.077.73.45
QUALITY
RETURN ON EQUITY-0.72%15.79%13.64%
RETURN ON CAPITAL-3.92%19.38%10.09%
NET MARGIN-6.58%14.46%9.73%
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATION/A
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
5 OUT OF 9
DEBT-TO-EQUITY2%
INTEREST COVERAGE4.7x
CURRENT RATIO3.28
GROWTH
5 YR EPS GROWTH-226.86%
5 YR SPS GROWTH3.83%
5 YR BPS GROWTH4.38%
Vertex Pharmaceuticals Inc News
Stocks Showing Market Leadership: Voyager Therapeutics Earns 91 RS Rating
On Tuesday Voyager Therapeutics VYGR hit an important technical milestone seeing its Relative Strength RS Rating jump into the 90 plus percentile with an improvement to 91 up from 87 the day before ibd display video id 2368044 width 50 float
January 16, 16:15:13 UTC

Can Vertex Pharmaceuticals Report Solid 2017 Net Profit Margins?
Should Investors Be Interested in Vertex Pharmaceuticals in 2018? In 3Q17, Vertex Pharmaceuticals (VRTX) reported non-GAAP (generally accepted accounting principals) net profits of ~$136 million, which is a YoY (year-over-year) growth of ~216.3%, driven mainly by the rapid rise in total cystic fibrosis (or CF) drug sales. The company reported non-GAAP combined SG&A (selling, general, and administrative) and R&D (research and development) expenses of ~$334 million, which is a YoY rise of 13.2%.
January 16, 15:45:02 UTC

Why Vertex Pharmaceuticals Raised Its 2017 Revenue Guidance
Should Investors Be Interested in Vertex Pharmaceuticals in 2018?
January 16, 14:15:02 UTC

Analyst Recommendations for Vertex Pharmaceuticals in January
Should Investors Be Interested in Vertex Pharmaceuticals in 2018?Financial performance in 3Q17
January 16, 12:40:41 UTC

Concert Pharmaceuticals Plunges on Patent Petition Setback
Shares of Concert Pharmaceuticals Inc CNCE plunged more than 25 following the announcement that the Patent Trial and Appeal Board PTAB of the U S Patent and Trademark Office has refused to grant the company a Post Grant Review petition in a dispute related to Incyte Corporation s
January 15, 22:06:27 UTC

Why Concert Pharmaceuticals, Inc. Is Singing the Blues Today
Bad news trumps good news for the biotech.
January 12, 20:18:00 UTC

Atara Biotherapeutics Joins Elite Club Of Stocks With RS Ratings Over 90
Atara Biotherapeutics ATRA had its Relative Strength RS Rating upgraded from 90 to 93 Friday ibd display video id 2368044 width 50 float left autostart true IBD s proprietary RS Rating tracks market leadership by showing how a stock s price movement over the
January 12, 16:09:08 UTC

The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
January 12, 14:16:02 UTC

PRTO On The Move, ARWR Hits A High, WVE Doesn't Wane, Big Events Await CHRS
PRTO On The Move, ARWR Hits A High, WVE Doesn't Wane, Big Events Await CHRS
January 11, 19:57:00 UTC

Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU
Vertex Pharmaceuticals Inc VRTX announced that the European Commission has approved an extension of the marketing application for its cystic fibrosis product Orkambi With the approval Orkambi s marketing label in EU will now include use in children with CF aged between six and 11 years
January 11, 17:07:11 UTC

Can Biotech Keep Last Year's Momentum Alive in 2018?
The year 2017 has been better than expected for the biotech sector The NASDAQ Biotechnology index was up 18 7 in 2017 While drug pricing issue competition and a slowdown in growth of key drugs are expected to remain a hangover in 2018 as well approval of new drugs and strategic acquisitions
January 11, 17:02:47 UTC

Biogen Trying To Close In On Key Technical Measure
The Relative Strength RS Rating for Biogen BIIB entered a higher percentile Thursday as it got a lift from 70 to 73 ibd display video id 2385970 width 50 float left autostart true This exclusive rating from Investor s Business Daily measures
January 11, 16:11:20 UTC

Heron Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90
On Thursday Heron Therapeutics HRTX earned an upgrade to its Relative Strength RS Rating from 86 to 92 ibd display video id 2881825 width 50 float left autostart true IBD s proprietary rating identifies share price movement with a 1 worst to 99
January 11, 16:09:22 UTC

Stocks With Rising Relative Price Strength: Regenxbio
Regenxbio RGNX had its Relative Strength RS Rating upgraded from 72 to 81 Thursday ibd display video id 2368044 width 50 float left autostart true IBD s unique rating measures price movement with a 1 worst to 99 best score The score shows how a stock
January 11, 16:09:10 UTC

Alder Biopharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark
Alder Biopharmaceuticals ALDR saw a positive improvement to its Relative Strength RS Rating on Thursday with an upgrade from 80 to 84 ibd display video id 2368044 width 50 float left autostart true This proprietary rating measures market leadership by using a
January 11, 16:09:02 UTC


Vertex Pharmaceuticals Inc (VRTX)
Healthcare | Drugs
155.30  -1.65%

Stocks Showing Market Leadership: Voyager Therapeutics Earns 91 RS Rating
On Tuesday Voyager Therapeutics VYGR hit an important technical milestone seeing its Relative Strength RS Rating jump into the 90 plus percentile with an improvement to 91 up from 87 the day before ibd display video id 2368044 width 50 float
January 16, 16:15:13 UTC

Can Vertex Pharmaceuticals Report Solid 2017 Net Profit Margins?
Should Investors Be Interested in Vertex Pharmaceuticals in 2018? In 3Q17, Vertex Pharmaceuticals (VRTX) reported non-GAAP (generally accepted accounting principals) net profits of ~$136 million, which is a YoY (year-over-year) growth of ~216.3%, driven mainly by the rapid rise in total cystic fibrosis (or CF) drug sales. The company reported non-GAAP combined SG&A (selling, general, and administrative) and R&D (research and development) expenses of ~$334 million, which is a YoY rise of 13.2%.
January 16, 15:45:02 UTC

Why Vertex Pharmaceuticals Raised Its 2017 Revenue Guidance
Should Investors Be Interested in Vertex Pharmaceuticals in 2018?
January 16, 14:15:02 UTC

Analyst Recommendations for Vertex Pharmaceuticals in January
Should Investors Be Interested in Vertex Pharmaceuticals in 2018?Financial performance in 3Q17
January 16, 12:40:41 UTC

Concert Pharmaceuticals Plunges on Patent Petition Setback
Shares of Concert Pharmaceuticals Inc CNCE plunged more than 25 following the announcement that the Patent Trial and Appeal Board PTAB of the U S Patent and Trademark Office has refused to grant the company a Post Grant Review petition in a dispute related to Incyte Corporation s
January 15, 22:06:27 UTC

Why Concert Pharmaceuticals, Inc. Is Singing the Blues Today
Bad news trumps good news for the biotech.
January 12, 20:18:00 UTC

Atara Biotherapeutics Joins Elite Club Of Stocks With RS Ratings Over 90
Atara Biotherapeutics ATRA had its Relative Strength RS Rating upgraded from 90 to 93 Friday ibd display video id 2368044 width 50 float left autostart true IBD s proprietary RS Rating tracks market leadership by showing how a stock s price movement over the
January 12, 16:09:08 UTC

The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
January 12, 14:16:02 UTC

PRTO On The Move, ARWR Hits A High, WVE Doesn't Wane, Big Events Await CHRS
PRTO On The Move, ARWR Hits A High, WVE Doesn't Wane, Big Events Await CHRS
January 11, 19:57:00 UTC

Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU
Vertex Pharmaceuticals Inc VRTX announced that the European Commission has approved an extension of the marketing application for its cystic fibrosis product Orkambi With the approval Orkambi s marketing label in EU will now include use in children with CF aged between six and 11 years
January 11, 17:07:11 UTC

Can Biotech Keep Last Year's Momentum Alive in 2018?
The year 2017 has been better than expected for the biotech sector The NASDAQ Biotechnology index was up 18 7 in 2017 While drug pricing issue competition and a slowdown in growth of key drugs are expected to remain a hangover in 2018 as well approval of new drugs and strategic acquisitions
January 11, 17:02:47 UTC

Biogen Trying To Close In On Key Technical Measure
The Relative Strength RS Rating for Biogen BIIB entered a higher percentile Thursday as it got a lift from 70 to 73 ibd display video id 2385970 width 50 float left autostart true This exclusive rating from Investor s Business Daily measures
January 11, 16:11:20 UTC

Heron Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90
On Thursday Heron Therapeutics HRTX earned an upgrade to its Relative Strength RS Rating from 86 to 92 ibd display video id 2881825 width 50 float left autostart true IBD s proprietary rating identifies share price movement with a 1 worst to 99
January 11, 16:09:22 UTC

Stocks With Rising Relative Price Strength: Regenxbio
Regenxbio RGNX had its Relative Strength RS Rating upgraded from 72 to 81 Thursday ibd display video id 2368044 width 50 float left autostart true IBD s unique rating measures price movement with a 1 worst to 99 best score The score shows how a stock
January 11, 16:09:10 UTC

Alder Biopharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark
Alder Biopharmaceuticals ALDR saw a positive improvement to its Relative Strength RS Rating on Thursday with an upgrade from 80 to 84 ibd display video id 2368044 width 50 float left autostart true This proprietary rating measures market leadership by using a
January 11, 16:09:02 UTC